Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BREAST IMPLANT LIABILITY SETTLEMENT MAXIMUM AWARD LOWERED TO $250,000; 190,000 WOMEN ELIGIBLE FOR REVISED PACT APPROVED BY BOARDS OF BAXTER, BMS, 3M

This article was originally published in The Gray Sheet

Executive Summary

A breast implant liability settlement plan that would award up to $250,000 on a per-patient basis has been approved by the boards of defendants Bristol-Myers Squibb, 3M and Baxter, the U.S. District Court of Alabama reported in a Nov. 13 recorded statement. The maximum compensation under the offer is lower than the amount outlined in an initial version announced by the court in October.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel